Mast Therapeutics, Inc. (NYSEMKT:MSTX)

CAPS Rating: 2 out of 5

A biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases.

Recs

1
Player Avatar pchop123 (76.55) Submitted: 7/17/2012 1:35:49 PM : Outperform Start Price: $0.71 MSTX Score: +2.41

Rockets away

Featured Broker Partners


Advertisement